Sanofi To Invest $1.05 Bln For New Insulin Production Base In China
(RTTNews) - French drug major Sanofi plans to invest around 1 billion euros or about $1.05 billion to build a new insulin manufacturing base in Beijing, China, reports said.
The move represents Sanofi's single largest investment in China so far, where it has been present for more than 40 years. The investment will boost the manufacturing of insulin to help diabetic patients in the region and enhance the company's supply-chain resilience.
The new site, located in an economic development zone in Yizhuang, will be Sanofi's second production base in Beijing and its fourth in the country.
Sanofi signed a memorandum of cooperation with the Beijing Municipal Bureau of Economy and Information Technology and the Beijing Economic-Technological Development Area or BDA Administrative Committee regarding the investment.
According to Sanofi Chief Executive Paul Hudson, the new production base will feature advanced automated production technologies, cutting-edge digital integrated management systems and sustainable environmental standards.
Medical journal the Lancet reportedly pointed that China now has the largest number of diabetes patients worldwide.
Sanofi And Biovac Ink Manufacturing Partnership To Make Inactivated Polio Vaccines In Africa
Sanofi, OpenAI To Build AI Software To Boost Drug Development
Sanofi Q1 Profit Weak, But Sales Rise; Backs FY24 View; Stock Up
Sanofi Q3 Profit Rises, Backs FY23 View, To Split Consumer Healthcare Unit; Stock Dips
Sanofi Q4 Profit Climbs, Sees Slower Earnings Growth In FY23; Stock Down
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Fed's Beige Book Says U.S. Economic Activity Rose Slightly
